DUBLIN, Sept. 9, 2021 /PRNewswire/ -- Comprehensive access to over 2600 Infectious Diseases deal records from this report, "Global Infectious Diseases Partnering 2014-2021: Deal trends, players and financials" that has been added to ResearchAndMarkets.com's offering.
Global Infectious Diseases Partnering 2014 to 2021 provides the full collection of Infectious Diseases disease deals signed between the world's pharmaceutical and biotechnology companies since 2014.
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive Infectious Diseases disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Infectious Diseases deals.
The report presents financial deal terms values for Infectious Diseases deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
The report also includes numerous tables and figures that illustrate the trends and activities in Infectious Diseases partnering and dealmaking since 2014.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Infectious Diseases technologies and products.
Report scope
Global Infectious Diseases Partnering 2014 to 2021 includes:
The report includes deals for the following indications:
In Global Infectious Diseases Partnering 2014 to 2021, available deals and contracts are listed by:
Analyzing actual contract agreements allows assessment of the following:
Key Topics Covered:
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in Infectious Diseases dealmaking
2.1. Introduction
2.2. Infectious Diseases partnering over the years
2.3. Infectious Diseases partnering by deal type
2.4. Infectious Diseases partnering by industry sector
2.5. Infectious Diseases partnering by stage of development
2.6. Infectious Diseases partnering by technology type
2.7. Infectious Diseases partnering by therapeutic indication
Chapter 3 -Financial deal terms for Infectious Diseases partnering
3.1. Introduction
3.2. Disclosed financials terms for Infectious Diseases partnering
3.3. Infectious Diseases partnering headline values
3.4. Infectious Diseases deal upfront payments
3.5. Infectious Diseases deal milestone payments
3.6. Infectious Diseases royalty rates
Chapter 4 - Leading Infectious Diseases deals and dealmakers
4.1. Introduction
4.2. Most active in Infectious Diseases partnering
4.3. List of most active dealmakers in Infectious Diseases
4.4. Top Infectious Diseases deals by value
Chapter 5 - Infectious Diseases contract document directory
5.1. Introduction
5.2. Infectious Diseases partnering deals where contract document available
Chapter 6 - Infectious Diseases dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by Infectious Diseases therapeutic target
Appendices
Appendix 1 - Directory of Infectious Diseases deals by company A-Z since 2014
Appendix 2 - Directory of Infectious Diseases deals by deal type since 2014
Appendix 3 - Directory of Infectious Diseases deals by stage of development since 2014
Appendix 4 - Directory of Infectious Diseases deals by technology type since 2014
For more information about this report visit https://www.researchandmarkets.com/r/5i95pc
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
These press releases may also interest you
|